Search academic texts

Information × Registration Number 0120U104687, ( 0221U106198  0221U106199  0221U106742  ) R & D request Title Study of the therapeutic effectiveness and safety of new equivalents of the dermis with the inclusion of a composite (the drug izatizon and the cytokine EMAP II) for the treatment of traumatic skin lesions Head Lukash Liubov L., Доктор біологічних наук Registration Date 06-11-2020 Organization Institute of Molecular Biology and Genetics of NAS of Ukraine popup.description1 Preclinical studies of safety and clinical efficiency of new dermal equivalents or dermal coatings which include the complex of cell-derived active compounds and composite of izatizon preparation with EMAP II cytokine for further implementation into clinical practice in thermal burns and other skin lesions treatment. Improvement of our existing experimental biotechnological product, the dermal equivalent, for further improvement of their therapeutic properties and reduction of production costs, will be provided for further human therapeutical application. New dermal equivalents can be used for thermal burn treatment and other traumatic skin lesions, trophical ulcers, contaminated wounds, and other complicated and difficult to heal skin damages, including those in diabetic patients. The rodent (mice, rats) thermal burn model is expected to be used as the main skin lesion model. popup.nrat_date 2024-12-10 Close